919 related articles for article (PubMed ID: 18473846)
1. Role of advanced glycation end products (AGEs) and oxidative stress in diabetic retinopathy.
Yamagishi S; Ueda S; Matsui T; Nakamura K; Okuda S
Curr Pharm Des; 2008; 14(10):962-8. PubMed ID: 18473846
[TBL] [Abstract][Full Text] [Related]
2. Advanced glycation end products (AGEs), oxidative stress and diabetic retinopathy.
Yamagishi S; Matsui T
Curr Pharm Biotechnol; 2011 Mar; 12(3):362-8. PubMed ID: 20939798
[TBL] [Abstract][Full Text] [Related]
3. Telmisartan inhibits advanced glycation end products (AGEs)-elicited endothelial cell injury by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gammaactivation.
Yamagishi S; Matsui T; Nakamura K; Takeuchi M; Inoue H
Protein Pept Lett; 2008; 15(8):850-3. PubMed ID: 18855759
[TBL] [Abstract][Full Text] [Related]
4. Receptor for advanced glycation end products (RAGE): a novel therapeutic target for diabetic vascular complication.
Yamagishi S; Nakamura K; Matsui T; Noda Y; Imaizumi T
Curr Pharm Des; 2008; 14(5):487-95. PubMed ID: 18289075
[TBL] [Abstract][Full Text] [Related]
5. Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end-product (AGE)-induced monocyte chemoattractant protein-1 expression in mesangial cells through downregulation of receptor for AGEs via peroxisome proliferator-activated receptor-gamma activation.
Matsui T; Yamagishi S; Ueda S; Nakamura K; Imaizumi T; Takeuchi M; Inoue H
J Int Med Res; 2007; 35(4):482-9. PubMed ID: 17697525
[TBL] [Abstract][Full Text] [Related]
6. Advanced glycation end products (AGEs) and their receptor (RAGE) system in diabetic retinopathy.
Yamagishi S; Nakamura K; Matsui T
Curr Drug Discov Technol; 2006 Mar; 3(1):83-8. PubMed ID: 16712466
[TBL] [Abstract][Full Text] [Related]
7. Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes.
Yamagishi S; Matsui T; Nakamura K
Curr Drug Targets; 2007 Oct; 8(10):1138-43. PubMed ID: 17979674
[TBL] [Abstract][Full Text] [Related]
8. The renin-angiotensin system and advanced glycation end-products in diabetic retinopathy: impacts and synergies.
Miller AG; Zhu T; Wilkinson-Berka JL
Curr Clin Pharmacol; 2013 Nov; 8(4):285-96. PubMed ID: 23173957
[TBL] [Abstract][Full Text] [Related]
9. Role of advanced glycation end products (AGEs) in thrombogenic abnormalities in diabetes.
Takenaka K; Yamagishi S; Matsui T; Nakamura K; Imaizumi T
Curr Neurovasc Res; 2006 Feb; 3(1):73-7. PubMed ID: 16472128
[TBL] [Abstract][Full Text] [Related]
10. Telmisartan, its potential therapeutic implications in cardiometabolic disorders.
Yamagishi S; Nakamura K
Recent Pat Cardiovasc Drug Discov; 2006 Jan; 1(1):79-83. PubMed ID: 18221077
[TBL] [Abstract][Full Text] [Related]
11. Advanced glycation end products (AGEs) and cardiovascular disease (CVD) in diabetes.
Yamagishi S; Matsui T; Ueda S; Nakamura K; Imaizumi T
Cardiovasc Hematol Agents Med Chem; 2007 Jul; 5(3):236-40. PubMed ID: 17630950
[TBL] [Abstract][Full Text] [Related]
12. AGEs and diabetic retinopathy.
Stitt AW
Invest Ophthalmol Vis Sci; 2010 Oct; 51(10):4867-74. PubMed ID: 20876889
[TBL] [Abstract][Full Text] [Related]
13. AGEs, RAGE, and diabetic retinopathy.
Zong H; Ward M; Stitt AW
Curr Diab Rep; 2011 Aug; 11(4):244-52. PubMed ID: 21590515
[TBL] [Abstract][Full Text] [Related]
14. Advanced glycation end products (AGEs) and diabetic vascular complications.
Yamagishi S; Nakamura K; Imaizumi T
Curr Diabetes Rev; 2005 Feb; 1(1):93-106. PubMed ID: 18220586
[TBL] [Abstract][Full Text] [Related]
15. [Glycation].
Yamagishi S
Nihon Rinsho; 2010 May; 68(5):809-13. PubMed ID: 20446573
[TBL] [Abstract][Full Text] [Related]
16. Inhibitors of advanced glycation end products (AGEs): potential utility for the treatment of cardiovascular disease.
Yamagishi S; Nakamura K; Matsui T; Ueda S; Noda Y; Imaizumi T
Cardiovasc Ther; 2008; 26(1):50-8. PubMed ID: 18466420
[TBL] [Abstract][Full Text] [Related]
17. Potential utility of statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in diabetic retinopathy.
Yamagishi S; Nakamura K; Matsui T; Sato T; Takeuchi M
Med Hypotheses; 2006; 66(5):1019-21. PubMed ID: 16188392
[TBL] [Abstract][Full Text] [Related]
18. Telmisartan inhibits expression of a receptor for advanced glycation end products (RAGE) in angiotensin-II-exposed endothelial cells and decreases serum levels of soluble RAGE in patients with essential hypertension.
Nakamura K; Yamagishi S; Nakamura Y; Takenaka K; Matsui T; Jinnouchi Y; Imaizumi T
Microvasc Res; 2005 Nov; 70(3):137-41. PubMed ID: 16271939
[TBL] [Abstract][Full Text] [Related]
19. Involvement of the toxic AGEs (TAGE)-RAGE system in the pathogenesis of diabetic vascular complications: a novel therapeutic strategy.
Takeuchi M; Takino J; Yamagishi S
Curr Drug Targets; 2010 Nov; 11(11):1468-82. PubMed ID: 20583971
[TBL] [Abstract][Full Text] [Related]
20. Blockade of the advanced glycation end products (AGEs) and their receptor (RAGE) system is a possible mechanism for sustained beneficial effects of multifactorial intervention on mortality in type 2 diabetes.
Yamagishi S; Matsui T; Nakamura K
Med Hypotheses; 2008 Nov; 71(5):749-51. PubMed ID: 18710793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
